A Phase 2 interventional study of Treatment with brimonidine eye drops 0.025% in Myopia, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Myopia with a site in Spain — 4 open to participants now, 9 under way, 1 of them phase 3. Myopia · Spain.
Among the 26 studies in Myopia with a site in Spain, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 2, and was the 23rd registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →4 of the 26 studies in Myopia with a site in Spain are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in Spain, United States
Ages 7–35
Ocus Innovation Ireland Limited · Sites in Spain, Albania, Italy and 2 more countries
Ages 3–17
Indizen Optical Technologies, S.L.U. · Sites in Spain, Portugal, United Kingdom
Ages 6–12 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 60 across the 23 interventional studies, 180 across the 3 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 26 have an industry lead sponsor. The 10 most frequent:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal is the lead sponsor of 84 studies on the registry; 23 are open to participants now.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myopia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07394556Indizen Optical Technologies, S.L.U.Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population | 2027-04 |
| NCT06996236Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalBrimonidine Eye Drops in the Prevention of Myopia Progression | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Myopia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.
For the prevention of myopia progression it is reasonable to use a local topical route in eye drops, since it avoids the occurrence of systemic side effects and the drug reaches the corresponding receptors at a higher concentration via the topical route. This route of administration has been previously used in animal models and in humans, with atropine, pirenzepine and brimonidine.
The concentration proposed (0.025%) in this study is the one used with relative success without side effects for atropine in humans, and has also been used in animal models for brimonidine itself. As this is a first study, the investigators do not propose the use of higher concentrations at this time. The proposed regimen (once a day) is the one commonly used in the treatment of myopia. Although at the concentration used it is used 3-4 times a day in other indications of brimonidine eye drops, given the longer duration of this treatment and the fact that it is a first study, the investigators opted for the once-daily regimen.
Since eye growth is relatively slow, a treatment duration of 1 to 2 years is necessary to assess the effect of the drug on myopia progression and eye axial length variation. In addition, in case of therapeutic use of brimonidine eye drops, it would be necessary to use it for long periods of time, not less than 2 years, so it is convenient to evaluate its behavior when used in long term regimens.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lumobry 0.25 mg/ml eye drops solution
Drug: Treatment with brimonidine eye drops 0.025%
Drug page: BrimonidineStudies of BrimonidineBrimonidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.
Effect of brimonidine eye drops 0.025% on myopia progression in children aged 6 to 14 years
Progression of myopia (change in spherical equivalent of refractive error) measured every 6 months (Auto-refractometry and Subjective refraction)
Time frame: 24 months
Progression of various ocular biometric variables in the children of the treated and control groups,
Myopia progression by measuring every 6 months: change in axial eye length
Time frame: 24 months
Progression of various ocular biometric variables in the children of the treated and control groups
Description: Myopia progression by measuring every 6 months: visual acuity
Time frame: 24 months
Progression of various ocular biometric variables in the children of the treated and control groups
Description: Myopia progression by measuring every 6 months: pupillometry/accommodation
Time frame: 24 Months
Progression of various ocular biometric variables in the children of the treated and control groups
Description: Myopia progression by measuring every 6 months: corneal topography
Time frame: 24 Months
Progression of various ocular biometric variables in the children of the treated and control groups
Description: Myopia progression by measuring every 6 months: intraocular pressure
Time frame: 24 Months
Progression of various ocular biometric variables in the children of the treated and control groups
Collecting adverse events
Time frame: 24 Months
Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jul 2025 → Dec 2025 and primary completion Jul 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal